

Global Cancer Generics Market Outlook 2018

<https://marketpublishers.com/r/G4F536CCD7CEN.html>

Date: July 2014

Pages: 100

Price: US\$ 1,400.00 (Single User License)

ID: G4F536CCD7CEN

Abstracts

With the advent of novel and innovative technologies, industries like healthcare and pharmaceutical are scaling newer heights. One such market is the oncology market. With global cancer incidences rising to almost 14.1 Million in 2012 and several blockbuster cancer drugs losing their patent protection, the market for cancer generics is bound to experience skyrocketing growth.

According to our latest research report “Global Cancer Generics Market Outlook 2018”, the global oncology market touched a mark of US\$ 91 Billion in 2013 and is poised to grow at a CAGR of approximately 6% over the next 5 year period. On the other hand, the market for cancer generics is expected to grow at 12%, reaching US\$ 21 Billion by 2018. Patent expiry, low cost, and better life expectancy would be the major boosting factors for the cancer generics industry.

Our report essentially elicits the cancer industry under 2 heads viz. global oncology market and global cancer generics market. Hereunder, cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to major indications is also discussed in depth, with emphasis on current and future incidences, regional analysis and patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added.

Apart from the above mentioned study parameters the dossier also contains an analysis of the top notch global cancer generics manufacturers. On a holistic basis, the report is primarily inclined towards an in-depth study of the global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labeling Cancer Generics as a field with substantial growth potential over the next few years.

Contents

1. ANALYST VIEW

2. RESEARCH METHODOLOGY

3. GLOBAL CANCER DRUGS MARKET OUTLOOK 2018

3.1 Cancer Incidences

3.2 Cancer Drug Market

4. GLOBAL CANCER GENERICS MARKET ANALYSIS 2018

5. CANCER GENERIC DRUGS INDUSTRY

5.1 Oral Generic Drugs

5.1.1 Arimidex (Anastrozole)

5.1.2 Femara (Letrozole)

5.1.3 Hycamtin (Topotecan)

5.1.4 Stivarga (Regorafenib)

5.1.5 Tarceva (Erlotinib)

5.1.6 Xalkori (Crizotinib)

5.1.7 Xeloda (Capecitabine)

5.2 Generic Injectables

5.2.1 Camptosar (Irinotecan Hydrochloride)

5.2.2 Eloxatin (Oxaliplatin)

5.2.3 Gemzar (Gemcitabine Hydrochloride)

5.2.4 Navelbine (Vinorelbine Tartrate)

5.2.5 Platinol (Cisplatin)

5.2.6 Taxol (Paclitaxel)

5.2.7 Taxotere (Docetaxel)

6. CANCER GENERICS MARKET: MAJOR INDICATIONS

6.1 Lung Cancer

6.1.1 Incidence Outlook

6.1.2 Commercialized Drugs

6.2 Breast Cancer

6.2.1 Incidence Outlook

- 6.2.2 Commercialized Drugs
- 6.3 Colorectal Cancer
 - 6.3.1 Incidence Outlook
 - 6.3.2 Commercialized Drugs
- 6.4 Stomach Cancer
 - 6.4.1 Incidence Outlook
 - 6.4.2 Commercialized Drugs
- 6.5 Prostate Cancer
 - 6.5.1 Incidence Outlook
 - 6.5.2 Commercialized Drugs

7. MARKET DYNAMICS

- 7.1 Indian Generic Cancer Drug Introduced in the US Market
- 7.2 Launch of Generic Drugs for Oncology
- 7.3 Increasing Cancer Burden Paving Way for Generics
- 7.4 Patent Expiry of Blockbuster Oncology Drugs
- 7.5 Strategic Collaborations

8. KEY PLAYERS

- 8.1 Fresenius Kabi AG
 - 8.1.1 Business Overview
 - 8.1.2 Key Financials
 - 8.1.3 Strategic Developments
- 8.2 Actavis Plc.
 - 8.2.1 Business Overview
 - 8.2.2 Key Financials
 - 8.2.3 Strategic Developments
- 8.3 Hospira
 - 8.3.1 Business Overview
 - 8.3.2 Key Financials
 - 8.3.3 Strategic Developments
- 8.4 Teva Pharmaceutical Industries Ltd.
 - 8.4.1 Business Overview
 - 8.4.2 Key Financials
 - 8.4.3 Strategic Developments
- 8.5 Mylan
 - 8.5.1 Business Overview

8.5.2 Key Financials

8.5.3 Strategic Developments

8.6 Sun Pharmaceuticals

8.6.1 Business Overview

8.6.2 Key Financials

8.6.3 Strategic Developments

List Of Figures

LIST OF FIGURES:

- Figure 3-1: Global - Number of New Cancer Cases (Million), 2012 & 2025
- Figure 3-2: Global - Cancer Incidences by Gender (Million), 2012
- Figure 3-3: Global - Cancer Drugs Market (Billion US\$), 2008-2013
- Figure 3-4: Global - Cancer Drugs Market (Billion US\$), 2014-2018
- Figure 3-5: Cancer Drugs Market Share by Geography (%), 2013
- Figure 3-6: Cancer Drugs Market Share by Geography (%), 2018
- Figure 3-7: Global - Cancer Treatment Modalities Revenue Share (%), 2013
- Figure 4-1: Global - Cancer Generics Market (Billion US\$), 2013-2018
- Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2012 & 2020
- Figure 6-2: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
- Figure 6-3: Global - Number of New Breast Cancer Cases (Million), 2012 & 2020
- Figure 6-4: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
- Figure 6-5: Global - Number of New Colorectal Cancer Cases (Million), 2012 & 2020
- Figure 6-6: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
- Figure 6-7: Global - Number of New Stomach Cancer Cases (Million), 2012 & 2020
- Figure 6-8: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
- Figure 6-9: Global - Number of New Prostate Cancer Cases (Million), 2012 & 2020
- Figure 6-10: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020
- Figure 8-1: Fresenius Kabi - Sales & Net Income (Billion US\$), 2012 & 2013
- Figure 8-2: Fresenius Kabi - Revenue Share by Region (%), 2013
- Figure 8-3: Fresenius Kabi - Revenue Share by Business Segment (%), 2013
- Figure 8-4: Actavis - Sales & Net Income (Billion US\$), 2012 & 2013
- Figure 8-5: Actavis - Revenue Share by Region (%), 2013
- Figure 8-6: Actavis - Revenue Share by Business Segment (%), 2013
- Figure 8-7: Hospira - Sales & Net Income (Billion US\$), 2012 & 2013
- Figure 8-8: Hospira - Revenue Share by Region (%), 2013
- Figure 8-9: Hospira - Revenue Share by Business Segment (%), 2013
- Figure 8-10: Teva - Sales & Net Income (Billion US\$), 2012 & 2013
- Figure 8-11: Teva - Revenue Share by Region (%), 2013
- Figure 8-12: Hospira - Revenue Share by Business Segment (%), 2013
- Figure 8-13: Mylan - Sales & Net Income (Billion US\$), 2012 & 2013
- Figure 8-14: Mylan - Revenue Share by Region (%), 2013
- Figure 8-15: Mylan - Revenue Share by Business Segment (%), 2013
- Figure 8-16: Sun Pharma - Sales & Net Income (Billion US\$), 2012-13/ 2013-14
- Figure 8-17: Sun Pharma - Revenue Share by Business Segment (%), 2013-14

List Of Tables

LIST OF TABLES:

Table 3-1: Most Prevalent Types of Cancer

Table 3-2: Top 10 Countries with Highest Cancer Prevalence Rates

Table 5-1: List of Companies Dealing in Generic Arimidex

Table 5-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)

Table 5-3: List of Companies Dealing in Generic Femara

Table 5-4: Cost Comparison of Generics and Branded Femara (Letrozole)

Table 5-5: List of Companies Dealing in Generic Hycamtin

Table 5-6: List of Companies Dealing in Generic Xeloda

Table 5-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)

Table 5-8: List of Companies Dealing in Generic Camptosar

Table 5-9: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)

Table 5-10: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)

Table 5-11: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)

Table 5-12: List of Companies Dealing in Generic Navelbine (Vinorelbine)

Table 5-13: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)

Table 5-14: List of Companies Dealing in Generic Platinol (Cisplatin)

Table 5-15: List of Companies Dealing in Generic Taxol (Paclitaxel)

Table 5-16: Cost Comparison of Generics and Branded Taxol (Paclitaxel)

Table 5-17: List of Companies Dealing in Generic Taxotere (Docetaxel)

Table 5-18: Cost Comparison of Generics and Branded Taxotere (Docetaxel)

Table 6-1: Top 10 Countries by Lung Cancer Incidences (2012)

Table 6-2: Global - Key Lung Cancer Drugs and Patent Expiry Status

Table 6-3: Top 10 Countries by Breast Cancer Incidences (2012)

Table 6-4: Global - Key Breast Cancer Drugs and Patent Expiry Status

Table 6-5: Top 10 Countries by Colorectal Cancer Incidences (2012)

Table 6-6: Global - Key Colorectal Cancer Drugs and Patent Expiry Status

Table 6-7: Top 10 Countries by Stomach Cancer Incidences (2012)

Table 6-8: Global - Key Stomach Cancer Drugs and Patent Expiry Status

Table 6-9: Top 10 Countries by Prostate Cancer Incidences (2012)

Table 6-10: Global - Key Prostate Cancer Drugs and Patent Expiry Status

Table 7-1: Global - Key Cancer Drugs and Patent Expiry Status

Table 8-1: Fresenius Kabi Pharmaceuticals - Key Cancer Generic Drugs

Table 8-2: Actavis - Key Cancer Generic Drugs

Table 8-3: Hospira - Key Cancer Generic Products

Table 8-4: Teva Pharmaceuticals - Key Cancer Generic Drugs

Table 8-5: Mylan - Key Cancer Generic Drugs

Table 8-6: Sun Pharmaceuticals - Key Cancer Generic Drugs

I would like to order

Product name: Global Cancer Generics Market Outlook 2018

Product link: <https://marketpublishers.com/r/G4F536CCD7CEN.html>

Price: US\$ 1,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4F536CCD7CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970